Tagged as: AbbVie v. Coherus

Coherus and AbbVie File Dueling Motions for Injunctive Relief Relating to Coherus’s HUMIRA Biosimilar

Our readers may recall that ten HUMIRA biosimilars have been licensed to launch, with Amgen’s AMJEVITA the only one to launch to date and nine others set to launch starting in July 2023.  On June 1, 2023, Coherus issued a press release announcing “that the company plans to launch YUSIMRY™…

Read More